Skip to main content
Top
Published in: Cardiology and Therapy 1/2020

Open Access 01-06-2020 | Dabigatran | Original Research

Incidence Rates of Bleeding and Emergency Surgery Due to Trauma or Fracture Among Japanese Patients with Non-valvular Atrial Fibrillation Receiving Oral Anticoagulation Therapy

Authors: Masahiro Yasaka, Hiroyuki Yokota, Michiyasu Suzuki, Teiichi Yamane, Yasuhisa Ono

Published in: Cardiology and Therapy | Issue 1/2020

Login to get access

Abstract

Introduction

In patients with nonvalvular atrial fibrillation (NVAF) receiving oral anticoagulants (OACs), reversal of coagulopathy can be achieved with specific reversal drugs such as idarucizumab, which is indicated for use in patients treated with dabigatran for cases of life-threatening or uncontrolled bleeding or during emergency procedures that may cause serious bleeding. This study examined the incidence rate (IR) of emergency surgeries and major bleeding episodes associated with fractures and trauma in Japanese patients with NVAF receiving OACs.

Methods

This retrospective, non-interventional analysis of health insurance claims was conducted using data from 62,888 OAC-naive adult patients with NVAF who initiated dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban between March 2011 and June 2016. The primary endpoint was overall IR of emergency surgery or major bleeding due to fracture or trauma.

Results

Overall IR of emergency surgery or major bleeding due to fracture or trauma considering outcomes until OAC discontinuation was 0.489 per 100 patient-years (PY) (95% confidence interval [CI] 0.406–0.572). Considering first OAC exposure only, the IR was 0.483 per 100 PY (95% CI 0.394–0.573). Emergency surgery/major bleeding events due to fracture or trauma was highest in those aged ≥ 75 years (0.611 per 100 PY [95% CI 0.481–0.741]).

Conclusions

Fewer than one in 200 patients per year with NVAF receiving OACs experience emergency surgeries and major bleeding episodes associated with fractures and trauma; however, the IR of these events is markedly higher in patients of advanced age.

Trial registration

ClinicalTrials.gov 207, NCT03254147.
Literature
1.
go back to reference Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.CrossRef Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.CrossRef
2.
go back to reference Inoue H, Nozawa T, Hirai T, et al. Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation. Circ J. 2006;70:651–6.CrossRef Inoue H, Nozawa T, Hirai T, et al. Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation. Circ J. 2006;70:651–6.CrossRef
3.
go back to reference Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:e269–367.PubMed Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:e269–367.PubMed
4.
go back to reference De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (section III). Position paper of the ESC working group on thrombosis—task force on anticoagulants in heart disease. Thromb Haemost. 2013;110:1087–107.CrossRef De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (section III). Position paper of the ESC working group on thrombosis—task force on anticoagulants in heart disease. Thromb Haemost. 2013;110:1087–107.CrossRef
5.
go back to reference Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e44S–e88S.CrossRef Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e44S–e88S.CrossRef
6.
go back to reference Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1998;114:445S–S46969.CrossRef Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1998;114:445S–S46969.CrossRef
7.
go back to reference Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467–507.CrossRef Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467–507.CrossRef
8.
go back to reference Yorkgitis BK, Zhang J, Rappold JF. Non-vitamin K antagonist oral anticoagulants: the clinician's new challenge. J Am Osteopath Assoc. 2015;115:612–21.CrossRef Yorkgitis BK, Zhang J, Rappold JF. Non-vitamin K antagonist oral anticoagulants: the clinician's new challenge. J Am Osteopath Assoc. 2015;115:612–21.CrossRef
9.
go back to reference Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87(Suppl 1):S141–S145145.CrossRef Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87(Suppl 1):S141–S145145.CrossRef
10.
go back to reference Omae T, Koh K, Kumemura M, Sakuraba S, Katsuda Y. Perioperative management of patients with atrial fibrillation receiving anticoagulant therapy. J Anesth. 2019;33:551–61.CrossRef Omae T, Koh K, Kumemura M, Sakuraba S, Katsuda Y. Perioperative management of patients with atrial fibrillation receiving anticoagulant therapy. J Anesth. 2019;33:551–61.CrossRef
11.
go back to reference Thomas S, Makris M. The reversal of anticoagulation in clinical practice. Clin Med (Lond). 2018;18:314–9.CrossRef Thomas S, Makris M. The reversal of anticoagulation in clinical practice. Clin Med (Lond). 2018;18:314–9.CrossRef
13.
go back to reference Kojima M, Endo A, Shiraishi A, Otomo Y. Age-related characteristics and outcomes for patients with severe trauma: analysis of Japan's nationwide trauma registry. Ann Emerg Med. 2019;73:281–90.CrossRef Kojima M, Endo A, Shiraishi A, Otomo Y. Age-related characteristics and outcomes for patients with severe trauma: analysis of Japan's nationwide trauma registry. Ann Emerg Med. 2019;73:281–90.CrossRef
14.
go back to reference Nishimura T, Naito H, Matsuyama S, et al. Geriatric trauma in patients ≥ 85 years old in an urban district of Japan. Acta Med Okayama. 2019;73:197–203.PubMed Nishimura T, Naito H, Matsuyama S, et al. Geriatric trauma in patients ≥ 85 years old in an urban district of Japan. Acta Med Okayama. 2019;73:197–203.PubMed
15.
go back to reference Kubota K, Ooba N, Kamijima Y, Sato K, Koide D. The use of anticoagulants in patients with non-valvular atrial fibrillation between 2005 and 2014: a drug utilization study using claims data in Japan. PLoS ONE. 2018;13:e0203380.CrossRef Kubota K, Ooba N, Kamijima Y, Sato K, Koide D. The use of anticoagulants in patients with non-valvular atrial fibrillation between 2005 and 2014: a drug utilization study using claims data in Japan. PLoS ONE. 2018;13:e0203380.CrossRef
16.
go back to reference Ohshima A, Koyama T, Ogawa A, et al. Oral anticoagulants usage in Japanese patients aged 18–74 years with non-valvular atrial fibrillation: a retrospective analysis based on insurance claims data. Fam Pract. 2019;36:685–92.CrossRef Ohshima A, Koyama T, Ogawa A, et al. Oral anticoagulants usage in Japanese patients aged 18–74 years with non-valvular atrial fibrillation: a retrospective analysis based on insurance claims data. Fam Pract. 2019;36:685–92.CrossRef
17.
go back to reference Tanaka S, Seto K, Kawakami K. Pharmacoepidemiology in Japan: medical databases and research achievements. J Pharm Health Care Sci. 2015;1:16.CrossRef Tanaka S, Seto K, Kawakami K. Pharmacoepidemiology in Japan: medical databases and research achievements. J Pharm Health Care Sci. 2015;1:16.CrossRef
18.
go back to reference Urushihara H, Taketsuna M, Liu Y, et al. Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational study using a Japanese hospital database. PLoS ONE. 2012;7:e53224.CrossRef Urushihara H, Taketsuna M, Liu Y, et al. Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational study using a Japanese hospital database. PLoS ONE. 2012;7:e53224.CrossRef
19.
go back to reference Amin A, Keshishian A, Trocio J, et al. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Curr Med Res Opin. 2017;33:1595–604.CrossRef Amin A, Keshishian A, Trocio J, et al. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Curr Med Res Opin. 2017;33:1595–604.CrossRef
20.
go back to reference Li XS, Deitelzweig S, Keshishian A, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost. 2017;117:1072–82.CrossRef Li XS, Deitelzweig S, Keshishian A, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost. 2017;117:1072–82.CrossRef
21.
go back to reference Lip GY, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016;116:975–86.CrossRef Lip GY, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016;116:975–86.CrossRef
22.
go back to reference Lee KT, Chang SH, Yeh YH, et al. The CHA(2)DS(2)-VASc score predicts major bleeding in non-valvular atrial fibrillation patients who take oral anticoagulants. J Clin Med. 2018;7:338.CrossRef Lee KT, Chang SH, Yeh YH, et al. The CHA(2)DS(2)-VASc score predicts major bleeding in non-valvular atrial fibrillation patients who take oral anticoagulants. J Clin Med. 2018;7:338.CrossRef
23.
go back to reference Nielsen PB, Skjoth F, Sogaard M, et al. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;356:j510.CrossRef Nielsen PB, Skjoth F, Sogaard M, et al. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;356:j510.CrossRef
24.
go back to reference Koretsune Y, Etoh T, Katsuda Y, et al. Risk profile and 1-year outcome of newly diagnosed atrial fibrillation in Japan—insights from GARFIELD-AF. Circ J. 2018;83:67–74.CrossRef Koretsune Y, Etoh T, Katsuda Y, et al. Risk profile and 1-year outcome of newly diagnosed atrial fibrillation in Japan—insights from GARFIELD-AF. Circ J. 2018;83:67–74.CrossRef
25.
go back to reference Kitazono T, Ikeda T, Ogawa S, et al. Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation. Heart Vessels. 2020;35:399–408.CrossRef Kitazono T, Ikeda T, Ogawa S, et al. Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation. Heart Vessels. 2020;35:399–408.CrossRef
26.
go back to reference Nishida T, Okumura Y, Yokoyama K, et al. Oral anticoagulant use and clinical outcomes in elderly Japanese patients: findings from the SAKURA AF Registry. Heart Vessels. 2019;34:2021–30.CrossRef Nishida T, Okumura Y, Yokoyama K, et al. Oral anticoagulant use and clinical outcomes in elderly Japanese patients: findings from the SAKURA AF Registry. Heart Vessels. 2019;34:2021–30.CrossRef
27.
go back to reference Okumura Y, Yokoyama K, Matsumoto N, et al. Three-year clinical outcomes associated with warfarin vs. direct oral anticoagulant use among Japanese patients with atrial fibrillation—findings from the SAKURA AF registry. Circ J. 2018;82:2500–9.CrossRef Okumura Y, Yokoyama K, Matsumoto N, et al. Three-year clinical outcomes associated with warfarin vs. direct oral anticoagulant use among Japanese patients with atrial fibrillation—findings from the SAKURA AF registry. Circ J. 2018;82:2500–9.CrossRef
28.
go back to reference Koretsune Y, Yamashita T, Yasaka M, et al. Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: a claims database analysis. J Cardiol. 2019;73:204–9.CrossRef Koretsune Y, Yamashita T, Yasaka M, et al. Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: a claims database analysis. J Cardiol. 2019;73:204–9.CrossRef
29.
go back to reference Wong H, Lovett N, Curry N, Shah K, Stanworth SJ. Antithrombotics in trauma: management strategies in the older patients. J Blood Med. 2017;8:165–74.CrossRef Wong H, Lovett N, Curry N, Shah K, Stanworth SJ. Antithrombotics in trauma: management strategies in the older patients. J Blood Med. 2017;8:165–74.CrossRef
30.
go back to reference Kudo D, Miyakoshi N, Hongo M, et al. An epidemiological study of traumatic spinal cord injuries in the fastest aging area in Japan. Spinal Cord. 2019;57:509–15.CrossRef Kudo D, Miyakoshi N, Hongo M, et al. An epidemiological study of traumatic spinal cord injuries in the fastest aging area in Japan. Spinal Cord. 2019;57:509–15.CrossRef
31.
go back to reference Orimo H, Yaegashi Y, Hosoi T, et al. Hip fracture incidence in Japan: estimates of new patients in 2012 and 25-year trends. Osteoporos Int. 2016;27:1777–844.CrossRef Orimo H, Yaegashi Y, Hosoi T, et al. Hip fracture incidence in Japan: estimates of new patients in 2012 and 25-year trends. Osteoporos Int. 2016;27:1777–844.CrossRef
32.
go back to reference Okuno K. Current status and future of traumatic brain injury treatment in Japan [in Japanese]. Jpn J Neurosurgery (Tokyo). 2018;27:17–24.CrossRef Okuno K. Current status and future of traumatic brain injury treatment in Japan [in Japanese]. Jpn J Neurosurgery (Tokyo). 2018;27:17–24.CrossRef
33.
go back to reference Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med. 2017;377:431–41.CrossRef Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med. 2017;377:431–41.CrossRef
Metadata
Title
Incidence Rates of Bleeding and Emergency Surgery Due to Trauma or Fracture Among Japanese Patients with Non-valvular Atrial Fibrillation Receiving Oral Anticoagulation Therapy
Authors
Masahiro Yasaka
Hiroyuki Yokota
Michiyasu Suzuki
Teiichi Yamane
Yasuhisa Ono
Publication date
01-06-2020
Publisher
Springer Healthcare
Published in
Cardiology and Therapy / Issue 1/2020
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI
https://doi.org/10.1007/s40119-020-00171-w

Other articles of this Issue 1/2020

Cardiology and Therapy 1/2020 Go to the issue